KCT0003558进行中（未招募）未知
Multicenter Phase II study to demonstrate clinical benefit of lenalidomide and dexamethasone in elderly unfit patients with newly diagnosed multiple myeloma
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 70(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Patients = 70 years unfit and ineligible transplantation in patients with newly diagnosed MM.
- •2.Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- •3.Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •4.Symptomatic MM based on standard CRAB criteria.
- •5.Patient has measurable disease, defined as follows:
- •- any quantifiable serum monoclonal protein value (generally, but not necessarily, = 0.5 g/dL of M-protein) and, where applicable,
- •- urine light-chain excretion of >200 mg/24 hours. For patients with oligo or non-secretory MM, it is required that they have
- •- Measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory MM with free light chains only in order to maximize interpretation of benefit results.
- •6.The frailty of the patient will be calculated by R-MCI and scoring according to renal function, pulmonary function, activity, frailty, age, and cytogenetics, 0-3 points are low risk (fit) risk (inadequate) and 7 or higher will be classified as high risk (frail). Only inadequate and frail can be included.
- •7.Patients must meet the following clinical laboratory criteria with 21 days of starting treatment:
- •-Absolute neutrophil count (ANC) = 1,000/mm3 and platelet = 50,000/mm3 (= 30,000/mm3 if myeloma involvement in the bone marrow is >50%)
- •-Total bilirubin = 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 x ULN.
- •-Calculated creatinine clearance = 30mL/min or creatinine < 3mg/dL.
- •8.Patients who are planned to receive lenalidomide according to license of lenalidomide and must be registered the Risk Management Program(Pregnancy Prevention Program) of each company.
排除标准
- •1.Pregnant or lactating females.
- •2.Male patients not agreeing to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study.
- •3.Females of childbearing potential not agreeing to use two acceptable methods for contraception (e.g. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- •4.Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days).
- •5.Any significant medical disease or conditions that, in the investigator's opinion, may interfere with protocol adherence or subject's ability to give informed consent or could place the subject at unacceptable risk.
- •6.Presence of clinical active infectious hepatitis type B or C, classified into Child-Pugh class C (see Appendix V) and HIV.
- •7.Presence of acute active infection requiring antibiotics or infiltrative pulmonary disease.
- •8.Contraindication to any of the required drugs or supportive treatments.
- •9.prior history of malignancies, other than MM, unless the subject had been free of disease for >= 3 years with the following exceptions: Basal cell CA of skin, Squamous cell CA of skin, CA in situ of cervix and breast, incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
- •10.Known allergy to any of the study medications, their analogues, or excipients in the various formulations.
- •11.Subjects with unstable cardiac disease: MI within 6 months before study participation, NYHA heart failure class III-IV, uncontrolled hypertension/atrial fibrillation,
- •12.Conditions requiring chronic steroid/immunosuppressive therapy such as RA, MS, lupus, that likely need additional steroid/IS treatment in addition to study treatment
- •13.Grade >=2 Peripheral neuropathy
- •14.Subjects who are unwilling or unable to undergo antithrombotic therapy
研究者
相似试验
已完成
2 期
Multicenter phase II trial to assess clinical benefit of zoledronic acid with neo adjuvant endocrine treatment and the relationship between zoledronic acid use and gammadelta T cells for postmenopausal breast cancer.Postmenopausal ER positive and HER2 negative primary breast cancerJPRN-UMIN000008701Breast Surgery, Graduate School of Medicine, Kyoto University75
招募中
2 期
C-PROWESS studyeo Ras Wild type metastatic colorectal cancerJPRN-jRCTs031210565Shinozaki Eiji30
已完成
不适用
Phase II Multicenter Clinical Trial to evaluate the immune response generation capacity and the safety of the ALVAC-HIVVCP1452 Vaccine administered alone and in combination with the MN rpg 120 / HIV-1 vaccine in humans from Brazil, Haiti, Peru and Trinidad and Tobago.-B23 Human immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in other conditionsB23PER-036-01FRED HUTCHINSON CANCER RESEARCH CENTER,
进行中（未招募）
1 期
Clinical Trial to evaluate safety and efficacy of cell therapy in patients with cicatricial conjuntivitisCicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and mucous membrane pemphigoid with ocular involvement.EUCTR2021-005486-40-ESFUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE20
尚未招募
2 期
Multicenter phase II trial to evaluate the efficacy of Abound (nutrition product including HMB, arginine, and glutamine) on the clinical course of anastomotic leakage after gastrectomy in patients with gastric cancerAnastomotic leakage after gastrectomy for gastric cancerJPRN-UMIN000028945agoya University20